[S02DA03, antipyrine, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Antipyrine.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Dihydroergotamine.]
[J01EC01, sulfamethoxazole, The metabolism of Dihydroergotamine can be decreased when combined with Sulfamethoxazole.]
[M04AB02, sulfinpyrazone, The metabolism of Dihydroergotamine can be increased when combined with Sulfinpyrazone.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Sulindac.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Sulpiride.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Sulthiame.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Azapropazone.]
[L02BA01, tamoxifen, The metabolism of Dihydroergotamine can be increased when combined with Tamoxifen.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Dihydroergotamine.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Dihydroergotamine.]
[R03CC03, terbutaline, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Terbutaline.]
[G03BA03, testosterone, The metabolism of Dihydroergotamine can be increased when combined with Testosterone.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tetracaine.]
[S03AA02, tetracycline, The metabolism of Dihydroergotamine can be decreased when combined with Tetracycline.]
[N05AE05, lurasidone, Dihydroergotamine may increase the hypotensive activities of Lurasidone.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Dihydroergotamine.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be decreased when Dihydroergotamine is combined with Apomorphine.]
[L04AX02, thalidomide, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Dihydroergotamine.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Thiethylperazine.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be decreased when combined with Dihydroergotamine.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Thiopental.]
[N05AB08, thioproperazine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Thioproperazine.]
[N05AC02, thioridazine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Thioridazine.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Thiothixene.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Moxisylyte.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tiapride.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tilidine.]
[S01ED01, timolol, Timolol may increase the vasoconstricting activities of Dihydroergotamine.]
[M02AX02, tolazoline, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Tolazoline.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Tolmetin.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Dihydroergotamine is combined with Tramadol.]
[N06AF04, tranylcypromine, The metabolism of Dihydroergotamine can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Dihydroergotamine.]
[S01BA05, triamcinolone, The metabolism of Dihydroergotamine can be increased when combined with Triamcinolone.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Triazolam.]
[C03AA06, trichlormethiazide, Dihydroergotamine may decrease the antihypertensive activities of Trichlormethiazide.]
[A03AB12, mepenzolate, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trifluoperazine.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Trifluperidol.]
[N05AA05, triflupromazine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[R03BA07, mometasone, The metabolism of Dihydroergotamine can be increased when combined with Mometasone.]
[A03AA05, trimebutine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Trimethadione.]
[C02BA01, trimethaphan, Dihydroergotamine may decrease the antihypertensive activities of Trimethaphan.]
[N06AA06, trimipramine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Trimipramine.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Triprolidine.]
[A03BB01, butylscopolamine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Dihydroergotamine can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, Dihydroergotamine may increase the vasoconstricting activities of Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Dihydroergotamine.]
[C09CA09, azilsartan medoxomil, Dihydroergotamine may decrease the antihypertensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tubocurarine.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Dihydroergotamine.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be decreased when combined with Dihydroergotamine.]
[A10BH05, linagliptin, The metabolism of Dihydroergotamine can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The risk or severity of adverse effects can be increased when Boceprevir is combined with Dihydroergotamine.]
[J05AP02, telaprevir, The metabolism of Dihydroergotamine can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Dihydroergotamine can be decreased when combined with Rilpivirine.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ezogabine.]
[R03AC18, indacaterol, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Indacaterol.]
[B01AC24, ticagrelor, The metabolism of Dihydroergotamine can be decreased when combined with Ticagrelor.]
[C08DA01, verapamil, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Verapamil.]
[N06AX09, viloxazine, The metabolism of Dihydroergotamine can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Dihydroergotamine can be increased when combined with Vinblastine.]
[C04AX07, vincamine, Dihydroergotamine may decrease the antihypertensive activities of Vincamine.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Dihydroergotamine.]
[L01CA03, vindesine, The metabolism of Vindesine can be decreased when combined with Dihydroergotamine.]
[A11HA03, vitamin E, The metabolism of Dihydroergotamine can be increased when combined with Vitamin E.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Dihydroergotamine.]
[N01AX15, xenon, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Xenon.]
[C03BA10, xipamide, Dihydroergotamine may decrease the antihypertensive activities of Xipamide.]
[N05AF05, zuclopenthixol, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Dihydroergotamine can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Levetiracetam.]
[L01EC01, vemurafenib, The metabolism of Dihydroergotamine can be increased when combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be decreased when combined with Dihydroergotamine.]
[L01ED01, crizotinib, The metabolism of Dihydroergotamine can be decreased when combined with Crizotinib.]
[R03DC01, zafirlukast, The metabolism of Dihydroergotamine can be decreased when combined with Zafirlukast.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Dihydroergotamine can be decreased when combined with Drospirenone.]
[N02BA01, aspirin, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Dihydroergotamine.]
[G04BD07, tolterodine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[C07AB03, atenolol, Atenolol may increase the vasoconstricting activities of Dihydroergotamine.]
[J02AC03, voriconazole, The serum concentration of Dihydroergotamine can be increased when it is combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Atracurium.]
[S01FA01, atropine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Dihydroergotamine.]
[R07AX02, ivacaftor, The metabolism of Dihydroergotamine can be decreased when combined with Ivacaftor.]
[H02AB11, prednylidene, The metabolism of Dihydroergotamine can be increased when combined with Prednylidene.]
[G04BE10, avanafil, Dihydroergotamine may increase the hypotensive activities of Avanafil.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Dihydroergotamine.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Lorcaserin is combined with Dihydroergotamine.]
[G04BD12, mirabegron, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Mirabegron.]
[V03AX03, cobicistat, The serum concentration of Dihydroergotamine can be increased when it is combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Dihydroergotamine can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Dihydroergotamine can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be decreased when combined with Dihydroergotamine.]
[C01CA18, octopamine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Octopamine.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be decreased when combined with Dihydroergotamine.]
[N05CA04, barbital, The metabolism of Dihydroergotamine can be increased when combined with Barbital.]
[J05AE04, nelfinavir, The metabolism of Dihydroergotamine can be decreased when combined with Nelfinavir.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Dihydroergotamine.]
[N04BD02, rasagiline, The metabolism of Dihydroergotamine can be decreased when combined with Rasagiline.]
[C08CA13, lercanidipine, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Lercanidipine.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Dihydroergotamine.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Dihydroergotamine.]
[N02CC03, zolmitriptan, The risk or severity of vasospastic reactions can be increased when Dihydroergotamine is combined with Zolmitriptan.]
[R06AC06, thonzylamine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Diethyl ether.]
[H01CB05, pasireotide, The metabolism of Dihydroergotamine can be decreased when combined with Pasireotide.]
[G04BE03, sildenafil, The risk or severity of hypotension and syncope can be increased when Sildenafil is combined with Dihydroergotamine.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Dihydroergotamine.]
[C10AX12, lomitapide, The metabolism of Dihydroergotamine can be decreased when combined with Lomitapide.]
[C04AX11, bencyclane, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Bencyclane.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Dihydroergotamine can be increased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, Dihydroergotamine may decrease the antihypertensive activities of Bendroflumethiazide.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be decreased when combined with Dihydroergotamine.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Benorilate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Benperidol.]
[A06AX06, tegaserod, The risk or severity of serotonin syndrome can be increased when Dihydroergotamine is combined with Tegaserod.]
[H03AA04, tiratricol, Tiratricol may increase the vasoconstricting activities of Dihydroergotamine.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Benzocaine.]
[M01AH01, celecoxib, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Celecoxib.]
[N02CC02, naratriptan, Dihydroergotamine may increase the vasoconstricting activities of Naratriptan.]
[L04AA18, everolimus, The metabolism of Everolimus can be decreased when combined with Dihydroergotamine.]
[N04AC01, benztropine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Dihydroergotamine can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Benzydamine.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Levomilnacipran.]
[C08EA02, bepridil, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Bepridil.]
[C02KX05, riociguat, Dihydroergotamine may decrease the antihypertensive activities of Riociguat.]
[C02KX04, macitentan, Dihydroergotamine may decrease the antihypertensive activities of Macitentan.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Dihydroergotamine.]
[N06AX26, vortioxetine, Dihydroergotamine may increase the vasoconstricting activities of Vortioxetine.]
[N03AF04, eslicarbazepine, The metabolism of Dihydroergotamine can be increased when combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Dihydroergotamine can be decreased when combined with Simeprevir.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Vigabatrin.]
[C01CA27, droxidopa, Dihydroergotamine may increase the hypertensive activities of Droxidopa.]
[C07AB04, acebutolol, Acebutolol may increase the vasoconstricting activities of Dihydroergotamine.]
[N05CH03, tasimelteon, The metabolism of Dihydroergotamine can be decreased when combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Dihydroergotamine can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Dihydroergotamine can be increased when combined with Apremilast.]
[L02BG02, formestane, The metabolism of Dihydroergotamine can be increased when combined with Formestane.]
[S03BA03, betamethasone, The metabolism of Dihydroergotamine can be increased when combined with Betamethasone.]
[S01ED02, betaxolol, Betaxolol may increase the vasoconstricting activities of Dihydroergotamine.]
[C02CC01, bethanidine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Bethanidine.]
[L04AC11, siltuximab, The metabolism of Dihydroergotamine can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Dihydroergotamine can be decreased when combined with Ceritinib.]
[B01AC26, vorapaxar, The metabolism of Dihydroergotamine can be decreased when combined with Vorapaxar.]
[A03BA03, hyoscyamine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Dihydroergotamine.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be decreased when combined with Dihydroergotamine.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Alfaxalone.]
[R03AC19, olodaterol, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Olodaterol.]
[D11AA01, glycopyrronium, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Dihydroergotamine.]
[J01XA05, oritavancin, The metabolism of Dihydroergotamine can be increased when combined with Oritavancin.]
[N05AA04, acepromazine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.]
[N04AA02, biperiden, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L01EX09, nintedanib, The metabolism of Dihydroergotamine can be decreased when combined with Nintedanib.]
[L01XK01, olaparib, The metabolism of Dihydroergotamine can be decreased when combined with Olaparib.]
[B01AA01, dicumarol, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Dicoumarol.]
[N06AX11, mirtazapine, Dihydroergotamine may increase the serotonergic activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Dihydroergotamine can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Dihydroergotamine can be decreased when combined with Palbociclib.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be decreased when combined with Dihydroergotamine.]
[N02BE01, acetaminophen, The metabolism of Dihydroergotamine can be increased when combined with Acetaminophen.]
[A03AA09, difemerine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tioclomarol.]
[J05AP06, asunaprevir, The metabolism of Dihydroergotamine can be increased when combined with Asunaprevir.]
[A07DA06, eluxadoline, The risk or severity of serotonin syndrome can be increased when Dihydroergotamine is combined with Eluxadoline.]
[N05AX16, brexpiprazole, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Brexpiprazole.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Dihydroergotamine.]
[G02CX02, flibanserin, Dihydroergotamine may increase the vasoconstricting activities of Flibanserin.]
[N05AX15, cariprazine, Dihydroergotamine may increase the vasoconstricting activities of Cariprazine.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Acemetacin.]
[S01EC01, acetazolamide, The metabolism of Dihydroergotamine can be decreased when combined with Acetazolamide.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Acetophenazine.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Dihydroergotamine.]
[J02AC05, isavuconazole, The metabolism of Dihydroergotamine can be increased when combined with Isavuconazole.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be decreased when combined with Dihydroergotamine.]
[J05AF13, tenofovir alafenamide, The metabolism of Dihydroergotamine can be decreased when combined with Tenofovir alafenamide.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be decreased when combined with Dihydroergotamine.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Dihydroergotamine.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Dihydroergotamine.]
[B01AC27, selexipag, Dihydroergotamine may decrease the antihypertensive activities of Selexipag.]
[G04CA01, alfuzosin, Dihydroergotamine may increase the hypotensive activities of Alfuzosin.]
[M04AB05, lesinurad, The metabolism of Dihydroergotamine can be increased when combined with Lesinurad.]
[A03FA05, alizapride, The therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Alizapride.]
[N05CA05, aprobarbital, The metabolism of Dihydroergotamine can be increased when combined with Aprobarbital.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Alminoprofen.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Brivaracetam.]
[L01XX52, venetoclax, The metabolism of Dihydroergotamine can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Bromazepam.]
[N04BC01, bromocriptine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bromocriptine.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Alverine.]
[R06AB01, brompheniramine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Amineptine.]
[C08CA01, amlodipine, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Amlodipine.]
[N05AX17, pimavanserin, The metabolism of Dihydroergotamine can be decreased when combined with Pimavanserin.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Aniracetam.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dihydroergotamine.]
[C07AA19, bupranolol, Bupranolol may increase the vasoconstricting activities of Dihydroergotamine.]
[N07BC01, buprenorphine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Buspirone.]
[L01AB01, busulfan, The metabolism of Busulfan can be decreased when combined with Dihydroergotamine.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Butorphanol.]
[S01GX07, azelastine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Dihydroergotamine can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The serum concentration of Dihydroergotamine can be increased when it is combined with Azithromycin.]
[L01EF02, ribociclib, The metabolism of Dihydroergotamine can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Balsalazide.]
[R03CC12, bambuterol, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Bambuterol.]
[N02BF02, pregabalin, The therapeutic efficacy of Dihydroergotamine can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Beclamide.]
[C09AA07, benazepril, Dihydroergotamine may decrease the antihypertensive activities of Benazepril.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Oxybuprocaine.]
[D05AX03, calcitriol, The metabolism of Dihydroergotamine can be increased when combined with Calcitriol.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Dihydroergotamine.]
[J05AE09, tipranavir, The metabolism of Dihydroergotamine can be decreased when combined with Tipranavir.]
[L04AB02, infliximab, The metabolism of Dihydroergotamine can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Dihydroergotamine can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Dihydroergotamine.]
[N04BD03, safinamide, The metabolism of Dihydroergotamine can be decreased when combined with Safinamide.]
[L04AC14, sarilumab, The metabolism of Dihydroergotamine can be increased when combined with Sarilumab.]
[D01AC10, bifonazole, The metabolism of Dihydroergotamine can be decreased when combined with Bifonazole.]
[L01XX59, enasidenib, The metabolism of Dihydroergotamine can be increased when combined with Enasidenib.]
[L01EH02, neratinib, The metabolism of Neratinib can be decreased when combined with Dihydroergotamine.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Dihydroergotamine.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be decreased when combined with Dihydroergotamine.]
[C07AB07, bisoprolol, Bisoprolol may increase the vasoconstricting activities of Dihydroergotamine.]
[R03AC17, bitolterol, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Bitolterol.]
[J05AG03, efavirenz, The metabolism of Dihydroergotamine can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, Bopindolol may increase the vasoconstricting activities of Dihydroergotamine.]
[N04AA11, bornaprine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[A03FA04, bromopride, The therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Bromopride.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Brotizolam.]
[R03BA02, budesonide, The metabolism of Dihydroergotamine can be increased when combined with Budesonide.]
[C04AX20, buflomedil, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Bumadizone.]
[L01EL02, acalabrutinib, The metabolism of Dihydroergotamine can be decreased when combined with Acalabrutinib.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Butobarbital.]
[J05AX18, letermovir, The metabolism of Dihydroergotamine can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Butriptyline.]
[N01BX04, capsaicin, The metabolism of Dihydroergotamine can be decreased when combined with Capsaicin.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Vinylbital.]
[C09AA01, captopril, Dihydroergotamine may decrease the antihypertensive activities of Captopril.]
[L02BB05, apalutamide, The metabolism of Dihydroergotamine can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Dihydroergotamine can be increased when combined with Carbamazepine.]
[A03AA03, camylofine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Carbinoxamine.]
[C07AG02, carvedilol, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Carvedilol.]
[B02BX09, fostamatinib, The metabolism of Dihydroergotamine can be decreased when combined with Fostamatinib.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Dihydroergotamine.]
[C07AB08, celiprolol, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Celiprolol.]
[L01XX62, ivosidenib, The metabolism of Dihydroergotamine can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Dihydroergotamine can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Dihydroergotamine can be increased when combined with Tecovirimat.]
[L01EM04, duvelisib, The metabolism of Dihydroergotamine can be decreased when combined with Duvelisib.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Dihydroergotamine.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Cetirizine.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Carbromal.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Chloroprocaine.]
[R06AA06, chlorphenoxamine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Lornoxicam.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Dihydroergotamine.]
[R03BB08, revefenacin, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L01ED05, lorlatinib, The metabolism of Dihydroergotamine can be increased when combined with Lorlatinib.]
[L04AA39, emapalumab, The metabolism of Dihydroergotamine can be increased when combined with Emapalumab.]
[L01EX13, gilteritinib, The therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Gilteritinib.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Dihydroergotamine.]
[C09AA08, cilazapril, Dihydroergotamine may decrease the antihypertensive activities of Cilazapril.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Dihydroergotamine.]
[A03FA08, cinitapride, Dihydroergotamine may increase the vasoconstricting activities of Cinitapride.]
[P02BX04, triclabendazole, The metabolism of Dihydroergotamine can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Dihydroergotamine.]
[L04AA42, siponimod, The metabolism of Siponimod can be decreased when combined with Dihydroergotamine.]
[J01FA09, clarithromycin, The serum concentration of Dihydroergotamine can be increased when it is combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Dihydroergotamine.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Brexanolone.]
[A03FA06, clebopride, The therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Clebopride.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Dihydroergotamine.]
[N05BA09, clobazam, The metabolism of Dihydroergotamine can be increased when combined with Clobazam.]
[H02AB14, cloprednol, The metabolism of Dihydroergotamine can be increased when combined with Cloprednol.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Cloxazolam.]
[C09CA06, candesartan, Dihydroergotamine may decrease the antihypertensive activities of Candesartan.]
[L04AB01, etanercept, The metabolism of Dihydroergotamine can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The metabolism of Dihydroergotamine can be increased when combined with Cortivazol.]
[L01EM03, alpelisib, The metabolism of Dihydroergotamine can be increased when combined with Alpelisib.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Dihydroergotamine.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Cyamemazine.]
[C03BX03, cicletanine, Dihydroergotamine may decrease the antihypertensive activities of Cicletanine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Dihydroergotamine.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be decreased when combined with Dihydroergotamine.]
[N07XX11, pitolisant, The serum concentration of Dihydroergotamine can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Dihydroergotamine can be decreased when combined with Pretomanid.]
[J01XX12, lefamulin, The serum concentration of Dihydroergotamine can be increased when it is combined with Lefamulin.]
[C03AA09, cyclothiazide, Dihydroergotamine may decrease the antihypertensive activities of Cyclothiazide.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Yohimbine.]
[J01DB01, cephalexin, The metabolism of Dihydroergotamine can be decreased when combined with Cephalexin.]
[J01DB09, cephradine, The metabolism of Dihydroergotamine can be increased when combined with Cefradine.]
[H02AB13, deflazacort, The metabolism of Dihydroergotamine can be increased when combined with Deflazacort.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Dihydroergotamine.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Dihydroergotamine.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Dihydroergotamine.]
[B06AX03, voxelotor, The serum concentration of Dihydroergotamine can be increased when it is combined with Voxelotor.]
[N03AX25, cenobamate, The serum concentration of Dihydroergotamine can be decreased when it is combined with Cenobamate.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Dexbrompheniramine.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Dezocine.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Lemborexant.]
[L01XX72, tazemetostat, The metabolism of Dihydroergotamine can be decreased when combined with Tazemetostat.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Lumateperone.]
[J05AB16, remdesivir, The metabolism of Dihydroergotamine can be decreased when combined with Remdesivir.]
[H02CA02, osilodrostat, The metabolism of Dihydroergotamine can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Dihydroergotamine can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, Dihydroergotamine may increase the vasoconstricting activities of Frovatriptan.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Dutasteride.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Dichloralphenazone.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Dihydrocodeine.]
[N02CC06, eletriptan, Dihydroergotamine may increase the vasoconstricting activities of Eletriptan.]
[M01AH02, rofecoxib, The metabolism of Dihydroergotamine can be increased when combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Dihydroergotamine can be increased when combined with Bexarotene.]
[C08CA16, clevidipine, The metabolism of Dihydroergotamine can be increased when combined with Clevidipine.]
[C01BD07, dronedarone, The serum concentration of Dihydroergotamine can be increased when it is combined with Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Valpromide.]
[J01FA13, dirithromycin, The metabolism of Dihydroergotamine can be decreased when combined with Dirithromycin.]
[S03AA08, chloramphenicol, The metabolism of Dihydroergotamine can be decreased when combined with Chloramphenicol.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Chlordiazepoxide.]
[C02AA06, methoserpidine, Dihydroergotamine may decrease the antihypertensive activities of Methoserpidine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Dihydroergotamine.]
[A03AA08, dihexyverine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[C01CA14, dopexamine, The risk or severity of adverse effects can be decreased when Dihydroergotamine is combined with Dopexamine.]
[D07XB03, fluprednidene, The metabolism of Dihydroergotamine can be increased when combined with Fluprednidene.]
[G04BD09, trospium, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Droxicam.]
[L01EX22, selpercatinib, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Selpercatinib.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Dyclonine.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Dihydroergotamine.]
[R06AX22, ebastine, The metabolism of Dihydroergotamine can be decreased when combined with Ebastine.]
[N05CD14, remimazolam, The risk or severity of sedation can be increased when Dihydroergotamine is combined with Remimazolam.]
[L04AC19, satralizumab, The serum concentration of Dihydroergotamine can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Dihydroergotamine is combined with Oliceridine.]
[L01EX23, pralsetinib, The metabolism of Dihydroergotamine can be increased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, Dihydroergotamine may decrease the antihypertensive activities of Chlorothiazide.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Chlorpromazine.]
[N05AF03, chlorprothixene, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[C03BA04, chlorthalidone, Dihydroergotamine may decrease the antihypertensive activities of Chlorthalidone.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Chlorzoxazone.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Etifoxine.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Ethenzamide.]
[N06BX18, vinpocetine, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ethyl loflazepate.]
[M01AB08, etodolac, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Etodolac.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Etofenamate.]
[B06AC06, berotralstat, The serum concentration of Dihydroergotamine can be increased when it is combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Dihydroergotamine can be decreased when combined with Lonafarnib.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Naxitamab.]
[P03AX07, abametapir, The serum concentration of Dihydroergotamine can be increased when it is combined with Abametapir.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Febarbamate.]
[N03AX10, felbamate, The metabolism of Dihydroergotamine can be increased when combined with Felbamate.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Fenbufen.]
[C01CA19, fenoldopam, The risk or severity of adverse effects can be decreased when Dihydroergotamine is combined with Fenoldopam.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Finasteride.]
[R03BA03, flunisolide, The metabolism of Dihydroergotamine can be increased when combined with Flunisolide.]
[R03CC15, formoterol, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Formoterol.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Trichloroethylene.]
[H04AA02, dasiglucagon, Dihydroergotamine may decrease the antihypertensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The metabolism of Dihydroergotamine can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Gabapentin.]
[N07CA02, cinnarizine, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Cinnarizine.]
[L01XX73, sotorasib, The serum concentration of Dihydroergotamine can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Dihydroergotamine can be decreased when combined with Infigratinib.]
[S03AA07, ciprofloxacin, The metabolism of Dihydroergotamine can be decreased when combined with Ciprofloxacin.]
[N06AB04, citalopram, The metabolism of Dihydroergotamine can be decreased when combined with Citalopram.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Dihydroergotamine.]
[P01CA03, fexinidazole, The metabolism of Dihydroergotamine can be decreased when combined with Fexinidazole.]
[L01XX74, belzutifan, The serum concentration of Dihydroergotamine can be decreased when it is combined with Belzutifan.]
[L01EB10, mobocertinib, The serum concentration of Dihydroergotamine can be decreased when it is combined with Mobocertinib.]
[L04AA59, avacopan, The metabolism of Dihydroergotamine can be decreased when combined with Avacopan.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Dihydroergotamine.]
[R03CC13, clenbuterol, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Clenbuterol.]
[J01FF01, clindamycin, The serum concentration of Dihydroergotamine can be increased when it is combined with Clindamycin.]
[N06AX25, St. John's wort extract, The metabolism of Dihydroergotamine can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Dihydroergotamine can be increased when it is combined with Asciminib.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Dihydroergotamine.]
[J04BA01, clofazimine, The metabolism of Dihydroergotamine can be decreased when combined with Clofazimine.]
[C10AB01, clofibrate, The metabolism of Dihydroergotamine can be increased when combined with Clofibrate.]
[B06AX04, mitapivat, The metabolism of Dihydroergotamine can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Dihydroergotamine can be increased when it is combined with Pacritinib.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Dihydroergotamine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Dihydroergotamine.]
[C01EB24, mavacamten, The serum concentration of Dihydroergotamine can be decreased when it is combined with Mavacamten.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Granisetron.]
[J05AX31, lenacapavir, The metabolism of Dihydroergotamine can be decreased when combined with Lenacapavir.]
[N05AH02, clozapine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Clozapine.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Halazepam.]
[H01AC08, somatrogon, The metabolism of Dihydroergotamine can be increased when combined with Somatrogon.]
[S02DA02, cocaine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, Dihydroergotamine may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Dihydroergotamine can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Dihydroergotamine.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Hexafluronium.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Dihydroergotamine.]
[A03AB10, hexocyclium, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Desflurane.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ifenprodil.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Imidazole salicylate.]
[J01FA15, telithromycin, The metabolism of Dihydroergotamine can be decreased when combined with Telithromycin.]
[B01AC10, indobufen, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Desloratadine.]
[M01AH03, valdecoxib, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Valdecoxib.]
[A03AX10, isometheptene, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Isometheptene.]
[N02CC05, almotriptan, Dihydroergotamine may increase the vasoconstricting activities of Almotriptan.]
[M01AH04, parecoxib, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Parecoxib.]
[J02AC02, itraconazole, The metabolism of Dihydroergotamine can be decreased when combined with Itraconazole.]
[N05BA10, ketazolam, The metabolism of Dihydroergotamine can be decreased when combined with Ketazolam.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Kebuzone.]
[L01EA01, imatinib, The serum concentration of Dihydroergotamine can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The serum concentration of Dihydroergotamine can be increased when it is combined with Posaconazole.]
[C08CA09, lacidipine, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Lacidipine.]
[N03AX09, lamotrigine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[S01BA03, cortisone, The metabolism of Dihydroergotamine can be increased when combined with Cortisone.]
[N07BC04, lofexidine, The therapeutic efficacy of Dihydroergotamine can be increased when used in combination with Lofexidine.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Lonazolac.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Lormetazepam.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Loxoprofen.]
[C09AA03, lisinopril, Dihydroergotamine may decrease the antihypertensive activities of Lisinopril.]
[C08CA11, manidipine, The metabolism of Dihydroergotamine can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Medifoxamine.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Mefenorex.]
[C07AA14, mepindolol, Mepindolol may increase the vasoconstricting activities of Dihydroergotamine.]
[H02AB15, meprednisone, The metabolism of Dihydroergotamine can be increased when combined with Meprednisone.]
[R06AD07, mequitazine, The metabolism of Dihydroergotamine can be decreased when combined with Mequitazine.]
[N04AA03, methixene, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[C04AX01, cyclandelate, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Cyclandelate.]
[R03CB02, methoxyphenamine, The therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Cyclobarbital.]
[C03DA04, eplerenone, Dihydroergotamine may decrease the antihypertensive activities of Eplerenone.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Melperone.]
[C03AA07, cyclopenthiazide, Dihydroergotamine may decrease the antihypertensive activities of Cyclopenthiazide.]
[J01FA03, midecamycin, The metabolism of Dihydroergotamine can be decreased when combined with Midecamycin.]
[L01AA01, cyclophosphamide, The metabolism of Dihydroergotamine can be increased when combined with Cyclophosphamide.]
[N06AX07, minaprine, The metabolism of Dihydroergotamine can be decreased when combined with Minaprine.]
[S01XA18, cyclosporine, The metabolism of Dihydroergotamine can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, The metabolism of Dihydroergotamine can be decreased when combined with Moclobemide.]
[N06BA07, modafinil, The metabolism of Dihydroergotamine can be increased when combined with Modafinil.]
[R06AX02, cyproheptadine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C09AA13, moexipril, Dihydroergotamine may decrease the antihypertensive activities of Moexipril.]
[C10AA07, rosuvastatin, The metabolism of Dihydroergotamine can be decreased when combined with Rosuvastatin.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Dihydroergotamine can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Moxonidine.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Dihydroergotamine.]
[M01AH05, etoricoxib, The metabolism of Dihydroergotamine can be decreased when combined with Etoricoxib.]
[G03XA01, danazol, The metabolism of Dihydroergotamine can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Dantrolene.]
[L01DB02, daunorubicin, The metabolism of Dihydroergotamine can be decreased when combined with Daunorubicin.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Deanol.]
[C02CC04, debrisoquin, Dihydroergotamine may decrease the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Dihydroergotamine.]
[M01AX01, nabumetone, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Nabumetone.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Nordazepam.]
[C07AB12, nebivolol, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Nebivolol.]
[N06AX06, nefazodone, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Niaprazine.]
[C01DX16, nicorandil, Dihydroergotamine may decrease the antihypertensive activities of Nicorandil.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tiagabine.]
[C01CA23, theodrenaline, Dihydroergotamine may decrease the hypertensive activities of Theodrenaline.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Cisatracurium.]
[C01CA05, norfenefrine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Norfenefrine.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Dihydroergotamine is combined with Escitalopram.]
[G04BD08, solifenacin, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[A07EC03, olsalazine, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Olsalazine.]
[N06AA01, desipramine, The metabolism of Dihydroergotamine can be decreased when combined with Desipramine.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Dihydroergotamine.]
[C09XA02, aliskiren, Dihydroergotamine may decrease the antihypertensive activities of Aliskiren.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Oxaprozin.]
[N03AF02, oxcarbazepine, The metabolism of Dihydroergotamine can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The metabolism of Dihydroergotamine can be increased when combined with Dexamethasone.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Oxiracetam.]
[N04AA08, dexetimide, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, The metabolism of Dihydroergotamine can be decreased when combined with Oxybutynin.]
[A08AA04, dexfenfluramine, The risk or severity of serotonin syndrome can be increased when Dihydroergotamine is combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Dihydroergotamine can be increased when combined with Adalimumab.]
[N06BA02, dextroamphetamine, The therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Amphetamine.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Dextromethorphan.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Paramethadione.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Paroxetine.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Diamorphine.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Diazepam.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Phenacemide.]
[V03AH01, diazoxide, Dihydroergotamine may decrease the antihypertensive activities of Diazoxide.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Phensuximide.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Cinchocaine.]
[S01BC03, diclofenac, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Diclofenac.]
[J01CF01, dicloxacillin, The metabolism of Dihydroergotamine can be increased when combined with Dicloxacillin.]
[A03AA07, dicyclomine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[C02DG01, pinacidil, Dihydroergotamine may decrease the antihypertensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Pinaverium.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Pipamperone.]
[A03AB14, pipenzolate, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be decreased when combined with Dihydroergotamine.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Dihydroergotamine.]
[R03CC07, pirbuterol, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Pirbuterol.]
[A08AA03, diethylpropion, The therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Diethylpropion.]
[L02AA01, diethylstilbestrol, The metabolism of Dihydroergotamine can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Dihydroergotamine can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The metabolism of Dihydroergotamine can be increased when combined with Difluocortolone.]
[A03AB11, poldine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Diflunisal.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be decreased when combined with Dihydroergotamine.]
[C02DB01, dihydralazine, Dihydroergotamine may decrease the antihypertensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, Dihydroergocristine may increase the vasoconstricting activities of Dihydroergotamine.]
[S01AA13, fusidic acid, The metabolism of Dihydroergotamine can be decreased when combined with Fusidic acid.]
[N07XX04, sodium oxybate, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[S02BA08, fluocinolone acetonide, The metabolism of Dihydroergotamine can be increased when combined with Fluocinolone acetonide.]
[M01AG01, mefenamic acid, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Mefenamic acid.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Hydromorphone.]
[J05AE08, atazanavir, The metabolism of Dihydroergotamine can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, Dihydroergotamine may decrease the antihypertensive activities of Treprostinil.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Dihydroergotamine can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Dimenhydrinate.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Pridinol.]
[R06AB03, dimethindene, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[R03CC08, procaterol, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Procaterol.]
[M02AX03, dimethyl sulfoxide, The metabolism of Dihydroergotamine can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Progabide.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Proglumetacin.]
[C05CA03, diosmin, The metabolism of Dihydroergotamine can be decreased when combined with Diosmin.]
[R06AA02, diphenhydramine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Quazepam.]
[C09AA06, quinapril, Dihydroergotamine may decrease the antihypertensive activities of Quinapril.]
[B01AC07, dipyridamole, The risk or severity of hypotension and syncope can be increased when Dipyridamole is combined with Dihydroergotamine.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Quinupramine.]
[A03FA02, cisapride, The metabolism of Dihydroergotamine can be decreased when combined with Cisapride.]
[C09AA05, ramipril, Dihydroergotamine may decrease the antihypertensive activities of Ramipril.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Dihydroergotamine.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Remoxipride.]
[R03CC14, reproterol, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Reproterol.]
[C01BA03, disopyramide, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S02AA12, rifamycin SV, The metabolism of Dihydroergotamine can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Dihydroergotamine can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Riluzole.]
[N05AX08, risperidone, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Risperidone.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Dihydroergotamine.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Dihydroergotamine.]
[A04AD12, aprepitant, The metabolism of Dihydroergotamine can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be decreased when combined with Dihydroergotamine.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Dihydroergotamine.]
[J05AE07, fosamprenavir, The metabolism of Dihydroergotamine can be decreased when combined with Fosamprenavir.]
[G04BE08, tadalafil, The risk or severity of hypotension and syncope can be increased when Tadalafil is combined with Dihydroergotamine.]
[S01BC05, ketorolac, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Ketorolac.]
[C02KX02, ambrisentan, Dihydroergotamine may decrease the antihypertensive activities of Ambrisentan.]
[C01EB18, ranolazine, The metabolism of Dihydroergotamine can be decreased when combined with Ranolazine.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Salsalate.]
[R03AC12, salmeterol, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Salmeterol.]
[C01CA07, dobutamine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Dobutamine.]
[A03FA03, domperidone, The therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Domperidone.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Dopamine.]
[N06AA16, dothiepin, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Dosulepin.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Doxapram.]
[N06AA12, doxepin, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxepin.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be decreased when combined with Dihydroergotamine.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dihydroergotamine.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Dihydroergotamine.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Sibutramine.]
[C09AA11, spirapril, Dihydroergotamine may decrease the antihypertensive activities of Spirapril.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Sultopride.]
[N02CC01, sumatriptan, Dihydroergotamine may increase the vasoconstricting activities of Sumatriptan.]
[G01AF05, econazole, The serum concentration of Dihydroergotamine can be increased when it is combined with Econazole.]
[C07AB13, talinolol, Talinolol may increase the vasoconstricting activities of Dihydroergotamine.]
[H01AA01, corticotropin, The metabolism of Dihydroergotamine can be increased when combined with Corticotropin.]
[M01AC02, tenoxicam, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Tenoxicam.]
[G04CA03, terazosin, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Terazosin.]
[D01BA02, terbinafine, The metabolism of Dihydroergotamine can be increased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Terodiline.]
[C07AA16, tertatolol, Tertatolol may increase the vasoconstricting activities of Dihydroergotamine.]
[S01GA02, tetrahydrozoline, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Tetryzoline.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Thiopropazate.]
[G04BD01, emepronium, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be decreased when combined with Dihydroergotamine.]
[C09AA02, enalapril, Dihydroergotamine may decrease the antihypertensive activities of Enalapril.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tofisopam.]
[M01AG02, tolfenamic acid, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Tolfenamic acid.]
[N06AG03, toloxatone, The metabolism of Dihydroergotamine can be decreased when combined with Toloxatone.]
[N06BA09, atomoxetine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Dihydroergotamine.]
[N03AX11, topiramate, The metabolism of Dihydroergotamine can be increased when combined with Topiramate.]
[C03CA04, torsemide, Dihydroergotamine may decrease the antihypertensive activities of Torasemide.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Tramazoline.]
[C09AA10, trandolapril, Dihydroergotamine may decrease the antihypertensive activities of Trandolapril.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Loprazolam.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Triclofos.]
[A03AB08, tridihexethyl, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Trimethobenzamide.]
[N04AA12, tropatepine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[R03CC11, tulobuterol, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Tulobuterol.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Dihydroergotamine.]
[C02CA06, urapidil, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Urapidil.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Veralipride.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be decreased when combined with Dihydroergotamine.]
[S01FB02, ephedrine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Ephedrine.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Epinastine.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Dihydroergotamine is combined with Venlafaxine.]
[C01CX07, xamoterol, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Xamoterol.]
[S01GA03, xylometazoline, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Xylometazoline.]
[C08CA12, mepirodipine, The metabolism of Dihydroergotamine can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The metabolism of Dihydroergotamine can be decreased when combined with Epinephrine.]
[C09AA15, zofenopril, Dihydroergotamine may decrease the antihypertensive activities of Zofenopril.]
[N05CF02, zolpidem, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Zonisamide.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Dihydroergotamine.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Zotepine.]
[C02AC02, guanfacine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Guanfacine.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Moricizine.]
[G02AB03, ergonovine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be decreased when Dihydroergotamine is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Ergotamine.]
[S01AA17, erythromycin, Erythromycin may increase the vasoconstricting activities of Dihydroergotamine.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Estazolam.]
[J04AK02, ethambutol, The metabolism of Dihydroergotamine can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The metabolism of Dihydroergotamine can be increased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Dihydroergotamine can be increased when combined with Fluticasone.]
[C01CA15, gepefrine, The therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dihydroergotamine.]
[N04AA05, profenamine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Ethosuximide.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ethotoin.]
[M01AC06, meloxicam, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Meloxicam.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ethylmorphine.]
[C01CA01, etilefrine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Etilefrine.]
[N01AX07, etomidate, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Etomidate.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Dihydroergotamine.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Sertindole.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Dihydroergotamine.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Dihydroergotamine.]
[R06AX12, terfenadine, The metabolism of Dihydroergotamine can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Dihydroergotamine can be decreased when combined with Fluvoxamine.]
[P02CA03, albendazole, The metabolism of Dihydroergotamine can be decreased when combined with Albendazole.]
[C08CA02, felodipine, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Fendiline.]
[N03AX26, fenfluramine, The risk or severity of serotonin syndrome can be increased when Dihydroergotamine is combined with Fenfluramine.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Fenoprofen.]
[R03CC04, fenoterol, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Fenoterol.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Dihydroergotamine.]
[R03CC02, albuterol, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Salbutamol.]
[G04BD02, flavoxate, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Floctafenine.]
[J01CF05, floxacillin, The metabolism of Dihydroergotamine can be increased when combined with Flucloxacillin.]
[J02AC01, fluconazole, The metabolism of Dihydroergotamine can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Flunitrazepam.]
[D07AC08, fluocinonide, The metabolism of Dihydroergotamine can be increased when combined with Fluocinonide.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Melitracen.]
[H02AB03, fluocortolone, The metabolism of Dihydroergotamine can be increased when combined with Fluocortolone.]
[V03AZ01, ethanol, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[N06AB03, fluoxetine, The risk or severity of serotonin syndrome can be increased when Dihydroergotamine is combined with Fluoxetine.]
[N05AF01, flupenthixol, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Fluphenazine.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Flurazepam.]
[S01BC04, flurbiprofen, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Fluspirilene.]
[N06BX17, adrafinil, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Adrafinil.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Alcuronium.]
[G01AX06, furazolidone, The metabolism of Dihydroergotamine can be decreased when combined with Furazolidone.]
[J05AE10, darunavir, The serum concentration of Dihydroergotamine can be increased when it is combined with Darunavir.]
[C03CA01, furosemide, Dihydroergotamine may decrease the antihypertensive activities of Furosemide.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Amisulpride.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Gallamine.]
[C08DA02, gallopamil, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Gallopamil.]
[N03AA04, barbexaclone, The metabolism of Dihydroergotamine can be increased when combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Bifemelane.]
[L01EA02, dasatinib, The metabolism of Dihydroergotamine can be decreased when combined with Dasatinib.]
[N04BC06, cabergoline, The risk or severity of adverse effects can be decreased when Cabergoline is combined with Dihydroergotamine.]
[J05AG04, etravirine, The metabolism of Dihydroergotamine can be increased when combined with Etravirine.]
[N03AD03, methsuximide, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Alfentanil.]
[L01EH01, lapatinib, The metabolism of Dihydroergotamine can be decreased when combined with Lapatinib.]
[A10BB01, glyburide, The metabolism of Dihydroergotamine can be decreased when combined with Glyburide.]
[N05CM18, dexmedetomidine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Dexmedetomidine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Glutethimide.]
[C05AE01, nitroglycerin, The bioavailability of Dihydroergotamine can be increased when combined with Nitroglycerin.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Dihydroergotamine.]
[C02CA04, doxazosin, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Doxazosin.]
[H01AB01, thyrotropin alfa, Thyrotropin alfa may increase the vasoconstricting activities of Dihydroergotamine.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Dihydroergotamine.]
[C07AB09, esmolol, Esmolol may increase the vasoconstricting activities of Dihydroergotamine.]
[B01AA12, fluindione, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Fluindione.]
[C09AA09, fosinopril, Dihydroergotamine may decrease the antihypertensive activities of Fosinopril.]
[D01BA01, griseofulvin, The metabolism of Dihydroergotamine can be increased when combined with Griseofulvin.]
[S01EX01, guanethidine, Dihydroergotamine may decrease the antihypertensive activities of Guanethidine.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Dihydroergotamine.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Halothane.]
[N05AH04, quetiapine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Quetiapine.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Iprazochrome.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be decreased when combined with Dihydroergotamine.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Allobarbital.]
[C09CA01, losartan, The metabolism of Dihydroergotamine can be decreased when combined with Losartan.]
[G03DC01, allylestrenol, The metabolism of Dihydroergotamine can be decreased when combined with Allylestrenol.]
[A07EC02, mesalamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Dihydroergotamine.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Hexobarbital.]
[R03CC05, hexoprenaline, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Hexoprenaline.]
[C08CA10, nilvadipine, The metabolism of Dihydroergotamine can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Nimesulide.]
[C09AA04, perindopril, Dihydroergotamine may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, The metabolism of Dihydroergotamine can be decreased when combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, Dihydroergotamine may decrease the antihypertensive activities of Hydrochlorothiazide.]
[R05DA03, hydrocodone, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[S02BA01, hydrocortisone, The metabolism of Dihydroergotamine can be increased when combined with Hydrocortisone.]
[C03AA02, hydroflumethiazide, Dihydroergotamine may decrease the antihypertensive activities of Hydroflumethiazide.]
[G04BD06, propiverine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Propiverine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Prothipendyl.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dihydroergotamine.]
[J04AB04, rifabutin, The metabolism of Dihydroergotamine can be increased when combined with Rifabutin.]
[C02AC06, rilmenidine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Rilmenidine.]
[R02AX02, ibuprofen, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Ibuprofen.]
[L01AA06, ifosfamide, The metabolism of Dihydroergotamine can be increased when combined with Ifosfamide.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Sufentanil.]
[N06AA02, imipramine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Imipramine.]
[L01CD01, paclitaxel, The metabolism of Dihydroergotamine can be increased when combined with Paclitaxel.]
[M03BX02, tizanidine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Tizanidine.]
[C03BA11, indapamide, Dihydroergotamine may decrease the antihypertensive activities of Indapamide.]
[S01BC01, indomethacin, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Indomethacin.]
[C02CA02, indoramin, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Indoramin.]
[N06AX17, milnacipran, The metabolism of Dihydroergotamine can be decreased when combined with Milnacipran.]
[A03AA30, piperidolate, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Articaine.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Dihydroergotamine.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ramelteon.]
[R06AE01, buclizine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C10AA06, cerivastatin, The metabolism of Dihydroergotamine can be increased when combined with Cerivastatin.]
[C07AA01, alprenolol, Alprenolol may increase the vasoconstricting activities of Dihydroergotamine.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Iprindole.]
[N06AF05, iproniazid, The metabolism of Dihydroergotamine can be decreased when combined with Iproniazid.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The metabolism of Dihydroergotamine can be decreased when combined with Isocarboxazid.]
[R03CC06, isoetharine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Isoetharine.]
[C09AA16, imidapril, Dihydroergotamine may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Isoflurane.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Entacapone.]
[J04AC01, isoniazid, The metabolism of Dihydroergotamine can be decreased when combined with Isoniazid.]
[R03CB01, isoproterenol, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Isoprenaline.]
[C04AA01, isoxsuprine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Isoxsuprine.]
[J01FA07, josamycin, The serum concentration of Dihydroergotamine can be increased when it is combined with Josamycin.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Dihydroergotamine.]
[L04AC07, tocilizumab, The metabolism of Dihydroergotamine can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ketanserin.]
[J02AB02, ketoconazole, The metabolism of Dihydroergotamine can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Ketoprofen.]
[V03AC03, deferasirox, The metabolism of Dihydroergotamine can be increased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Dihydroergotamine can be increased when combined with Abatacept.]
[C01CA22, arbutamine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Arbutamine.]
[N04BC09, rotigotine, Dihydroergotamine may increase the sedative activities of Rotigotine.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Tiaprofenic acid.]
[C07AG01, labetalol, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Labetalol.]
[N04BB01, amantadine, The risk or severity of serotonin syndrome can be increased when Dihydroergotamine is combined with Amantadine.]
[C02AA05, deserpidine, Dihydroergotamine may decrease the antihypertensive activities of Deserpidine.]
[N03AX18, lacosamide, The metabolism of Dihydroergotamine can be decreased when combined with Lacosamide.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Lidoflazine.]
[N06BA13, armodafinil, The metabolism of Dihydroergotamine can be increased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Dihydroergotamine.]
[N02CA07, lisuride, The risk or severity of adverse effects can be decreased when Dihydroergotamine is combined with Lisuride.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Lofepramine.]
[A07DA03, loperamide, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Loperamide.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Dihydroergotamine.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Dihydroergotamine.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Loxapine.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Dihydroergotamine.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Dihydroergotamine can be increased when used in combination with Magnesium sulfate.]
[L01EA03, nilotinib, The metabolism of Dihydroergotamine can be decreased when combined with Nilotinib.]
[N06AA21, maprotiline, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Mazindol.]
[C02BB01, mecamylamine, Dihydroergotamine may decrease the antihypertensive activities of Mecamylamine.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Meclizine.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Meclofenamic acid.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Medazepam.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Melatonin.]
[N02AB02, meperidine, The metabolism of Dihydroergotamine can be decreased when combined with Meperidine.]
[C01CA11, mephentermine, The therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Mephentermine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Mephenytoin.]
[N03AA01, mephobarbital, The metabolism of Dihydroergotamine can be increased when combined with Methylphenobarbital.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Meprobamate.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Meptazinol.]
[L02BG01, aminoglutethimide, The metabolism of Dihydroergotamine can be increased when combined with Aminoglutethimide.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Mesoridazine.]
[N05AX13, paliperidone, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.]
[C01CA09, metaraminol, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Metaraminol.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Dolasetron.]
[H01CB03, lanreotide, The metabolism of Dihydroergotamine can be decreased when combined with Lanreotide.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Dihydroergotamine.]
[N06BA03, methamphetamine, The therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Metamfetamine.]
[A03AB07, methantheline, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Methaqualone.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Metharbital.]
[G02CB05, metergoline, The risk or severity of adverse effects can be decreased when Dihydroergotamine is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Dihydroergotamine can be decreased when combined with Methimazole.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Methocarbamol.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Methohexital.]
[N02BG08, ziconotide, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Ziconotide.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be decreased when combined with Dihydroergotamine.]
[N05AA02, methotrimeprazine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA10, methoxamine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Methoxamine.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Methoxyflurane.]
[C02AB01, methyldopa, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Methyldopa.]
[V04CG05, methylene blue, Dihydroergotamine may increase the serotonergic activities of Methylene blue.]
[G02AB01, methylergonovine, The metabolism of Dihydroergotamine can be decreased when combined with Methylergometrine.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Dihydroergotamine.]
[N06BA04, methylphenidate, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Methylphenidate.]
[H02AB04, methylprednisolone, The metabolism of Dihydroergotamine can be increased when combined with Methylprednisolone.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Dihydroergotamine.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Methyprylon.]
[N02CA04, methysergide, Methysergide may increase the vasoconstricting activities of Dihydroergotamine.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Dihydroergotamine.]
[C03BA08, metolazone, Dihydroergotamine may decrease the antihypertensive activities of Metolazone.]
[C07AB02, metoprolol, Metoprolol may increase the vasoconstricting activities of Dihydroergotamine.]
[P01AB01, metronidazole, The metabolism of Dihydroergotamine can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, The metabolism of Dihydroergotamine can be increased when combined with Metyrapone.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Dihydroergotamine can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Aminophenazone.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Dihydroergotamine.]
[C01CA17, midodrine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Midodrine.]
[G03XB01, mifepristone, The serum concentration of Dihydroergotamine can be increased when it is combined with Mifepristone.]
[C09CA03, valsartan, Dihydroergotamine may decrease the antihypertensive activities of Valsartan.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dihydroergotamine.]
[D11AX01, minoxidil, Dihydroergotamine may decrease the antihypertensive activities of Minoxidil.]
[J01FA11, miocamycin, The metabolism of Dihydroergotamine can be decreased when combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Dihydroergotamine can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Lisdexamfetamine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Molindone.]
[L03AC01, aldesleukin, The metabolism of Dihydroergotamine can be decreased when combined with Aldesleukin.]
[C01BD01, amiodarone, The metabolism of Dihydroergotamine can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Amitriptyline.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Dihydroergotamine.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Palonosetron.]
[L04AB05, certolizumab pegol, The metabolism of Dihydroergotamine can be increased when combined with Certolizumab pegol.]
[L01EX03, pazopanib, The metabolism of Dihydroergotamine can be decreased when combined with Pazopanib.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Vecuronium.]
[N05CA02, amobarbital, The metabolism of Dihydroergotamine can be increased when combined with Amobarbital.]
[G04CA04, silodosin, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.]
[G03XC01, raloxifene, The metabolism of Dihydroergotamine can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Amoxapine.]
[N03AB05, fosphenytoin, The metabolism of Dihydroergotamine can be increased when combined with Fosphenytoin.]
[C07AA12, nadolol, Nadolol may increase the vasoconstricting activities of Dihydroergotamine.]
[N04BC04, ropinirole, Dihydroergotamine may increase the sedative activities of Ropinirole.]
[J01CF06, nafcillin, The metabolism of Dihydroergotamine can be increased when combined with Nafcillin.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Nalbuphine.]
[V03AB15, naloxone, The metabolism of Dihydroergotamine can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of serotonin syndrome can be increased when Dihydroergotamine is combined with Naltrexone.]
[L04AC03, anakinra, The metabolism of Dihydroergotamine can be increased when combined with Anakinra.]
[S01GA01, naphazoline, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Naphazoline.]
[N06BA01, amphetamine, The therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Amphetamine.]
[M02AA12, naproxen, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Naproxen.]
[A10BG01, troglitazone, The metabolism of Dihydroergotamine can be increased when combined with Troglitazone.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tolcapone.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Dihydroergotamine.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Remifentanil.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Dihydroergotamine.]
[N06AX23, desvenlafaxine, The metabolism of Dihydroergotamine can be decreased when combined with Desvenlafaxine.]
[C09CA07, telmisartan, Dihydroergotamine may decrease the antihypertensive activities of Telmisartan.]
[C10AD02, niacin, The metabolism of Dihydroergotamine can be decreased when combined with Niacin.]
[N06AF02, nialamide, The metabolism of Dihydroergotamine can be decreased when combined with Nialamide.]
[C08CA04, nicardipine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nicardipine.]
[C04AE02, nicergoline, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nicergoline.]
[C08CA05, nifedipine, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Nifedipine.]
[M02AA17, niflumic acid, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Niflumic acid.]
[C08CA06, nimodipine, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Nimodipine.]
[C08CA07, nisoldipine, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Nisoldipine.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Nitrazepam.]
[C08CA08, nitrendipine, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Nitrendipine.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Zaleplon.]
[N04BC05, pramipexole, Dihydroergotamine may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, Dihydroergotamine may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Nomifensine.]
[C01CA03, norepinephrine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Norepinephrine.]
[G03DC02, norethindrone, The metabolism of Dihydroergotamine can be decreased when combined with Norethisterone.]
[C02KX01, bosentan, The metabolism of Dihydroergotamine can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Nortriptyline.]
[R05DA07, noscapine, The metabolism of Dihydroergotamine can be decreased when combined with Noscapine.]
[G02CA02, nylidrin, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Nylidrin.]
[H01CB02, octreotide, The serum concentration of Dihydroergotamine can be increased when it is combined with Octreotide.]
[J01FA05, oleandomycin, The metabolism of Dihydroergotamine can be decreased when combined with Oleandomycin.]
[L04AC04, rilonacept, The metabolism of Dihydroergotamine can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Dihydroergotamine can be increased when combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Opium.]
[R03CB03, metaproterenol, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Orciprenaline.]
[G02CB04, quinagolide, The risk or severity of adverse effects can be decreased when Dihydroergotamine is combined with Quinagolide.]
[G04CA02, tamsulosin, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Tamsulosin.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Oxazepam.]
[C07AA02, oxprenolol, Oxprenolol may increase the vasoconstricting activities of Dihydroergotamine.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Oxycodone.]
[C01DX03, oxyfedrine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Oxyfedrine.]
[S01GA04, oxymetazoline, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[H01BB02, oxytocin, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Oxytocin.]
[N05AH05, asenapine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dihydroergotamine.]
[M03AC01, pancuronium, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[N05CC05, paraldehyde, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[H02AB05, paramethasone, The metabolism of Dihydroergotamine can be increased when combined with Paramethasone.]
[C02KC01, pargyline, The metabolism of Dihydroergotamine can be decreased when combined with Pargyline.]
[G04BD11, fesoterodine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, Penbutolol may increase the vasoconstricting activities of Dihydroergotamine.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Penfluridol.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Pentazocine.]
[N05CA01, pentobarbital, The metabolism of Dihydroergotamine can be increased when combined with Pentobarbital.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be decreased when Dihydroergotamine is combined with Pergolide.]
[C08EX02, perhexiline, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Perhexiline.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Perphenazine.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Phenazocine.]
[N06AF03, phenelzine, The metabolism of Dihydroergotamine can be decreased when combined with Phenelzine.]
[B01AA02, phenindione, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Phenindione.]
[N03AA02, phenobarbital, The metabolism of Dihydroergotamine can be increased when combined with Phenobarbital.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Phenoperidine.]
[C04AX02, phenoxybenzamine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Phenoxybenzamine.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Dihydroergotamine.]
[A08AA01, phentermine, The therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Phentermine.]
[V03AB36, phentolamine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Phentolamine.]
[M02AA01, phenylbutazone, The metabolism of Dihydroergotamine can be increased when combined with Phenylbutazone.]
[S01GA05, phenylephrine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Phenylephrine.]
[R01BA01, phenylpropanolamine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Phenylpropanolamine.]
[N03AB02, phenytoin, The metabolism of Dihydroergotamine can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Dihydroergotamine can be increased when combined with Golimumab.]
[L02BB03, bicalutamide, The metabolism of Dihydroergotamine can be decreased when combined with Bicalutamide.]
[C08CX01, mibefradil, The metabolism of Dihydroergotamine can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Dihydroergotamine.]
[C07AA03, pindolol, Pindolol may increase the vasoconstricting activities of Dihydroergotamine.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Dihydroergotamine.]
[J05AE01, saquinavir, The metabolism of Dihydroergotamine can be decreased when combined with Saquinavir.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Pipotiazine.]
[C09CA02, eprosartan, Dihydroergotamine may decrease the antihypertensive activities of Eprosartan.]
[A02BX03, pirenzepine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N04BC08, piribedil, The risk or severity of adverse effects can be decreased when Dihydroergotamine is combined with Piribedil.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Piritramide.]
[S01BC06, piroxicam, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Piroxicam.]
[N02CX01, pizotyline, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Dihydroergotamine can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Dihydroergotamine can be decreased when combined with Irbesartan.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Proxibarbal.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Dihydroergotamine can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, Dihydroergotamine may decrease the antihypertensive activities of Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Dihydroergotamine can be increased when it is combined with Ritonavir.]
[C07AB01, practolol, Practolol may increase the vasoconstricting activities of Dihydroergotamine.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Prazepam.]
[C02CA01, prazosin, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Prazosin.]
[S03BA02, prednisolone, The metabolism of Dihydroergotamine can be increased when combined with Prednisolone.]
[C01DX02, prenylamine, The risk or severity of hypotension can be increased when Dihydroergotamine is combined with Prenylamine.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Dihydroergotamine can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Dihydroergotamine can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Dihydroergotamine can be increased when combined with Probenecid.]
[S01HA05, procaine, The metabolism of Dihydroergotamine can be decreased when combined with Procaine.]
[L01XB01, procarbazine, The metabolism of Dihydroergotamine can be decreased when combined with Procarbazine.]
[C10AB05, fenofibrate, The metabolism of Dihydroergotamine can be decreased when combined with Fenofibrate.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Prochlorperazine.]
[N04AA04, procyclidine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[N05AA03, promazine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Promazine.]
[R06AD02, promethazine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[C01BC03, propafenone, Propafenone may increase the vasoconstricting activities of Dihydroergotamine.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Propanidid.]
[A03AB05, propantheline, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Periciazine.]
[N05CM06, propiomazine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Propiomazine.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Dihydroergotamine.]
[N01AX10, propofol, The metabolism of Dihydroergotamine can be decreased when combined with Propofol.]
[N02AC04, propoxyphene, The metabolism of Dihydroergotamine can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, Propranolol may increase the vasoconstricting activities of Dihydroergotamine.]
[N02CC04, rizatriptan, Dihydroergotamine may increase the vasoconstricting activities of Rizatriptan.]
[B01AC09, epoprostenol, Dihydroergotamine may decrease the antihypertensive activities of Epoprostenol.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Protriptyline.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Pseudoephedrine.]
[N05AX12, aripiprazole, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.]
[A03AB15, diphemanil, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Dihydroergotamine.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Pyrantel.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Mepyramine.]
[C01BA01, quinidine, Dihydroergotamine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Quinidine.]
[P01BC01, quinine, The metabolism of Dihydroergotamine can be increased when combined with Quinine.]
[C02AA01, rescinnamine, Dihydroergotamine may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Reserpine.]
[J04AB02, rifampin, The metabolism of Dihydroergotamine can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Rimiterol.]
[G02CA01, ritodrine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Ritodrine.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Oxitriptan.]
[J01FA06, roxithromycin, Roxithromycin may increase the vasoconstricting activities of Dihydroergotamine.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Salicylic acid.]
[S01FA02, scopolamine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The metabolism of Dihydroergotamine can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The metabolism of Dihydroergotamine can be decreased when combined with Selegiline.]
[H01CB01, somatostatin, The metabolism of Dihydroergotamine can be decreased when combined with Somatostatin.]
[C07AA07, sotalol, Sotalol may increase the vasoconstricting activities of Dihydroergotamine.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Dihydroergotamine.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Chloral hydrate.]
[N03AG01, valproic acid, The metabolism of Dihydroergotamine can be decreased when combined with Valproic acid.]
[D07AB02, hydrocortisone butyrate, The metabolism of Dihydroergotamine can be increased when combined with Hydrocortisone butyrate.]
[H02CA04, levoketoconazole, The metabolism of Dihydroergotamine can be decreased when combined with Levoketoconazole.]
[R03BB01, ipratropium bromide, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[J05AE02, indinavir, CYP3A4 inhibitors - ergot alkaloids and derivatives]
[J02AC03, voriconazole, CYP3A4 inhibitors - ergot alkaloids and derivatives]
[J05AE04, nelfinavir, CYP3A4 inhibitors - ergot alkaloids and derivatives]
[J05AE09, tipranavir, CYP3A4 inhibitors - ergot alkaloids and derivatives]
[J01FA09, clarithromycin, CYP3A4 inhibitors - ergot alkaloids and derivatives]
[J05AE05, amprenavir, CYP3A4 inhibitors - ergot alkaloids and derivatives]
[J01FA15, telithromycin, CYP3A4 inhibitors - ergot alkaloids and derivatives]
[J02AC02, itraconazole, CYP3A4 inhibitors - ergot alkaloids and derivatives]
[J05AE08, atazanavir, CYP3A4 inhibitors - ergot alkaloids and derivatives]
[S01AA17, erythromycin, CYP3A4 inhibitors - ergot alkaloids and derivatives]
[J05AE10, darunavir, CYP3A4 inhibitors - ergot alkaloids and derivatives]
[J02AB02, ketoconazole, CYP3A4 inhibitors - ergot alkaloids and derivatives]
[J05AE01, saquinavir, CYP3A4 inhibitors - ergot alkaloids and derivatives]
[J05AE03, ritonavir, CYP3A4 inhibitors - ergot alkaloids and derivatives]
